Jim Cramer had several picks on the Stop Trading! segment on CNBC today. The most noteworthy were his banking picks based on the Barclays (NYSE: BCS) and ABN AMRO (NYSE: ABN) merger and the biotech picks based on the AstraZeneca (NYSE: AZN) acquisition of MedImmune Inc. (NASDAQ: MEDI).
On Barclays buying ABN AMRO, Cramer said the takeaway could potentially be a higher price if a competing bid looks close, and that can help other bank values. SunTrust Banks Inc. (NYSE: STI), Fifth Third Bancorp. (NASDAQ: FITB), and Comerica Inc. (NYSE: CMA) were all noted as potential deals. If you go back and peer through the valuations of the larger regionals, these all come up as potential names that could be acquired; and noted that Bank of America (NYSE: BAC) is addicted to buyouts.
On MedImmune, Cramer thinks that the overpayment by AstraZeneca means a potential higher valuation adjustment for Cephalon Inc. (NASDAQ: CEPH) and Celgene Corp. (NASDAQ: CELG).
Cramer also rushed in a "I Like Coal too," and Arch Coal Inc. (NYSE: ACI) was his name.
Cramer's bank and biotech picks
Posted Apr 23rd 2007 3:50PM by Jon Ogg
Filed under: Analyst reports, Bank of America (BAC), Comerica Inc (CMA), Barclays plc ADS (BCS)
Advanced Micro Devices rallies after settling Intel tiff
United Technologies fires up a deal with GE
Cramer on BloggingStocks: Not much time left for downside 
